EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP 2 poison anti‐cancer drug etoposide

Ian G Cowell iD, Caroline A Austin iD

FEBS Open Bio · 2024-06 · 14 (6) · 1001-1010

DOI: 10.1002/2211-5463.13799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 26.03.2024. Verfasst von Ian G Cowell und 1 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences Institute, Newcastle University, UK. Hauptthemen laut MEDLINE: DNA Damage, DNA Topoisomerases, Type II, Etoposide, Peroxidase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: J G W Patterson Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloperoxidase (MPO) is found almost exclusively in granulocytes and immature myeloid cells. It plays a key role in the innate immune system, catalysing the formation of reactive oxygen species that are important in anti‐microbial action, but MPO also oxidatively transforms the topoisomerase II (TOP2) poison etoposide to chemical forms that have elevated DNA damaging properties. TOP2 poisons such as etoposide are widely used anti‐cancer drugs, but they are linked to cases of secondary acute myeloid leukaemias through a mechanism that involves DNA damage and presumably erroneous repair leading to leukaemogenic chromosome translocations. This leads to the possibility that myeloperoxidase inhibitors could reduce the rate of therapy‐related leukaemia by protecting haematopoietic cells from TOP2 poison‐mediated genotoxic damage while preserving the anti‐cancer efficacy of the treatment. We show here that myeloperoxidase inhibition reduces etoposide‐induced TOP2B‐DNA covalent complexes and resulting DNA double‐strand break formation in primary ex vivo expanded CD34 + progenitor cells and unfractionated bone marrow mononuclear cells. Since MPO inhibitors are currently being developed as anti‐inflammatory agents this raises the possibility that repurposing of these potential new drugs could provide a means of suppressing secondary acute myeloid leukaemias associated with therapies containing TOP2 poisons.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA DamageDNA Topoisomerases, Type IIEtoposidePeroxidasePoly-ADP-Ribose Binding ProteinsHumansAntineoplastic AgentsBone Marrow CellsDNA Breaks, Double-StrandedLeukocytes, MononuclearTopoisomerase II Inhibitors

Stichwörter der Autor:innen

DNA damageTOP2etoposidemyeloperoxidasemyelotoxicitytopoisomerase

Substanzen

Antineoplastic AgentsDNA Topoisomerases, Type IIEtoposideMPO protein, humanPeroxidasePoly-ADP-Ribose Binding ProteinsTOP2B protein, humanTopoisomerase II Inhibitors

Autor:innen und Institutionen

  • Biosciences Institute, Newcastle University, UK.

ORCID-Profile: Ian G Cowell, Caroline A Austin

Förderung

  • J G W Patterson Foundation

Zitieren

APA

Cowell, I. G., & Austin, C. A. (2024). Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP 2 poison anti‐cancer drug etoposide. FEBS Open Bio, 14(6), 1001-1010. https://doi.org/10.1002/2211-5463.13799

Vancouver

Cowell IG, Austin CA. Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP 2 poison anti‐cancer drug etoposide. FEBS Open Bio. 2024;14(6):1001-1010. doi:10.1002/2211-5463.13799

BibTeX
@article{Cowell2024,
  author = {Cowell, Ian G and Austin, Caroline A},
  title = {Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP 2 poison anti‐cancer drug etoposide},
  journal = {FEBS Open Bio},
  year = {2024},
  volume = {14},
  number = {6},
  pages = {1001--1010},
  doi = {10.1002/2211-5463.13799}
}
Kostenlos starten →